GLP-1s Are Reshaping Healthcare: Is Your Organization Ready for What Comes Next?
Glucagon-Like Peptide-1 (GLP-1) medications have largely been discussed as a pharmaceutical and clinical story. Increasingly, however, they are becoming a healthcare strategy story. A recent Wells Fargo analysis highlighted by Fierce Healthcare suggests that widespread GLP-1 use could disrupt a healthcare system that has historically invested significant resources in treating the downstream consequences of obesity (Fierce Healthcare, 2026). As treatment moves further upstream, healthcare organizations may need to reconsider everything from service-line projections and utilization…
